Thanks to our commitment to R&D, coupled with innovation, the excellence of our employees and our strong skills, Chiesi has reached important milestones. In fact, our company has become a benchmark in R&D in areas such as respiratory, neonatology and rare diseases. Associations and partnerships are an integral part of our innovation strategy. We work within a network of strategic alliances in which we include other pharmaceutical companies, medical centres of excellence, public and private institutions, and start-ups, among others.

The European Commission Ranking of the indicators of industrial investment in R&D in 2017/2018 includes the 2,500 private sector companies that invest the largest amounts of money in research and development in the world. These companies, based in 46 countries, invested a total of €736.4 million, representing approximately 90% of the R&D financed by companies around the world.

Chiesi managed to place itself in the global ranking for that financial year in position 41 within the top 50 biopharmaceutical companies. This would be reflected in the financial percentage dedicated to R&D that would correspond to 22.3%, with an increase in spending of 10.6 points (Δ) and with around €376 million allocated to this relevant work.

Chiesi has more than 540 employees dedicated exclusively to research activities at its own centres around the world. Chiesi’s R&D activity is mainly carried out at centres located in Italy, France, the United Kingdom, Sweden and the United States.